CSIMarket Company Name, Ticker, Suppliers, else..
 
Arcturus Therapeutics Holdings Inc   (NASDAQ: ARCT)
Other Ticker:  
 
 
Price: $17.9500 $-0.41 -2.233%
Day's High: $18.86 Week Perf: 4.24 %
Day's Low: $ 17.70 30 Day Perf: 0.73 %
Volume (M): 278 52 Wk High: $ 45.00
Volume (M$): $ 4,983 52 Wk Avg: $27.23
Open: $18.47 52 Wk Low: $14.93



 Market Capitalization (Millions $) 486
 Shares Outstanding (Millions) 27
 Employees 180
 Revenues (TTM) (Millions $) 160
 Net Income (TTM) (Millions $) -63
 Cash Flow (TTM) (Millions $) -75
 Capital Exp. (TTM) (Millions $) 2

Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc (Arcturus) is a clinical stage biopharmaceutical company engaged in the discovery, development, and commercialization of RNA medicines. The company is headquartered in San Diego, California, and was founded in 201

Arcturus has developed a proprietary mRNA drug delivery platform called STARR (Self-Transcribing Active Replicating RNA). This platform allows for rapid and flexible development of RNA medicines that can target a variety of diseases. The main focus of the company is on developing RNA medicines for the treatment of rare diseases and vaccines for infectious diseases.

The company has a pipeline of RNA medicines at various stages of development. ARCT-021 is the lead product candidate, which is being developed in collaboration with Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson). This candidate is being developed for the treatment of COVID-19 and is currently in Phase 2 clinical trials.

Arcturus is also developing ARCT-810, a potential treatment for ornithine transcarbamylase (OTC) deficiency, a rare genetic disorder. The company has received orphan drug designation for this candidate from the US FDA.

In addition to its own pipeline, Arcturus has formed partnerships with other pharmaceutical companies to develop RNA medicines for various indications. The company has partnerships with Ultragenyx Pharmaceutical and CureVac for the development of RNA medicines for rare diseases.

Arcturus has also entered into strategic alliances with various companies such as Thermo Fisher Scientific, Duke-NUS Medical School, and others to further advance its mRNA technology platform.

Arcturus has a strong management team with expertise in RNA technology, drug discovery, and development. The company has raised capital through various sources, including public offerings, private placements, and collaborations. As of 2021, the company has a market capitalization of approximately $4 billion.


   Company Address: 10628 Science Center Drive San Diego 92121 CA
   Company Phone Number: 900-2660   Stock Exchange / Ticker: NASDAQ ARCT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -5.7%    
DVAX        0.62% 
EBS   -6.34%    
OPK        5.03% 
PFE   -1.76%    
REGN   -2.17%    
• View Complete Report
   



Business Update

Groundbreaking Study Shows Enhanced Immunogenicity of Self-Amplifying mRNA COVID-19 Vaccine Compared to Conventional ...

Published Mon, Sep 30 2024 1:47 PM UTC

In a pivotal development within the COVID-19 vaccination landscape, CSL (ASX: CSL; USOTC: CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) have unveiled results from a head-to-head clinical trial that highlights the superior immunogenicity of a self-amplifying mRNA (sa-mRNA) COVID-19 vaccine over the conventional mRNA vaccine, Comirnaty, even at the one-year mark post-vaccina...
Business Update

Promising Results Highlight the Efficacy and Safety of ARCT-154: The World's First Approved Self-Amplifying mRNA COVID-19 Vaccine

Published Mon, May 20 2024 1:41 PM UTC

CSIMarket.com is pleased to present groundbreaking research published in Nature Communications, which sheds light on the safety, immunogenicity, and efficacy of ARCT-154. This innovative vaccine, developed by CSL and Arcturus Therapeutics, represents the world's first approved self-amplifying (sa-mRNA) COVID-19 vaccine.In an integrated phase 1/2/3a/3b study, researchers i...
Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc Surpasses Expectations with Impressive Third Quarter 2023 Earnings Results

Arcturus Therapeutics Holdings Inc, a leading biotech company, recently announced its earnings for the third quarter of the 2023 earnings season. The financial results showed significant improvements compared to the same period last year, indicating a positive trend for the company.
One of the key highlights from the earnings report was a decrease in the loss per share. Arcturus Therapeutics reported a loss of $-0.61 per share, compared to $-1.33 per share in the previous year. This is a substantial improvement, showing the company's efforts to reduce losses and improve profitability.
Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Faces Record-Breaking Challenges in Q2 2023

Financial News Report: Major Pharmaceutical Preparations Company Reports Disastrous Q2 2023 Results
On Wednesday, Major Pharmaceutical Preparations company announced its second-quarter financial results for 2023, revealing a disastrous quarter that saw a significant decline in revenue and a widened net loss per share. The company reported a revenue decline of -61.174%, amounting to $10.52 million, compared to the same reporting period last year. Similarly, the net loss per share surged to $-1.98, indicating a significant deterioration compared to the previous year.
In contrast to Major Pharmaceutical Preparations company's poor performance, the overall sector witnessed a rise in revenue during the second quarter of 2023. The sector's revenue increased, reaching $1.87 per share, while Major Pharmaceutical Preparations company's revenue tumbled by -86.898%, plummeting to $80.29 million.
Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc Shows Positive Income Growth Amidst Various Concerns

Investors in the stock market need to approach Arcturus Therapeutics Holdings Inc with caution in light of the recent announcements. While the company achieved an impressive return on investment of 42.66% in the first quarter of 2023, this is significantly higher than its average return on investment of 3.67%. However, it is essential to note that 156 other companies in the Healthcare sector outperformed ARCT in terms of return on investment.
Additionally, the company's total ranking has deteriorated from 0 to 1578 compared to the fourth quarter of 2022, indicating a decline in performance. The decline in net income is another cause for concern, although the company has improved its return on investment compared to the previous quarter.






Arcturus Therapeutics Holdings Inc's Segments
Collaboration Revenue    93.14 % of total Revenue
Grant Revenue    6.86 % of total Revenue
CSL Seqirus Collaboration Revenue    93.07 % of total Revenue
Other Collaboration Revenue Collaboration Revenue    0.07 % of total Revenue
BARDA Grant Revenue    6.86 % of total Revenue





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com